Document Detail

Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types.
MedLine Citation:
PMID:  9425388     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: We have investigated the prevalence of MEN 1 in patients with recognized pituitary adenomas. Since hyperparathyroidism is present in nearly 95-100% of patients with MEN 1 and frequently is the first condition to be identified, the study was limited to the identification of patients with hyperparathyroidism while the screening for gastroenteropancreatic (GEP) lesions was carried out in patients with both pituitary and parathyroid lesions. PATIENTS AND MEASUREMENTS: Serum total and ionized calcium, phosphate and intact PTH 1-84 (EASIA) were measured in 166 patients (68 with non-functioning pituitary adenoma, 42 with prolactinoma, 35 with GH-secreting adenoma, 17-with ACTH-screening adenoma, 1 with TSH-secreting adenoma, 1 with FSH-secreting adenoma and 2 with an only alpha-subunit secreting adenoma) referred to our clinic from 1990 to 1996. Plasma gastrin, somatostatin, pancreatic polypeptide and vasoactive intestinal peptide were measured by RIA in patients with hyperparathyroidism. RESULTS: Eight of 166 patients (4.8%) were found to have primary hyperparathyroidism and among these 2 also had a gastrinoma while there was no evidence of other GEP tumours. Considering the tumour type, 6 had prolactinoma (14.3%), 1 GH-secreting adenoma (2.8%) and 1 non-functioning adenoma (1.5%). In most patients the diagnosis of pituitary tumour was made several years before that of hyperparathyroidism (from 1 to 15 years) although 6 patients had previously suffered from urolithiasis and one had undergone gastric resections for recurrent peptic ulcers. One patient was identified as a MEN 1 gene carrier and 2 had relatives with signs and symptoms referable to parathyroid or GEP lesions. CONCLUSIONS: The study shows a prevalence of 4.8% of primary hyperparathyroidism in unselected patients with known pituitary tumours similar to that reported in a previous study. By contrast, the prevalence of MEN 1 in patients with prolactinoma was definitely high (14.3%). In most patients the diagnosis of pituitary tumours was made several years before that of hyperparathyroidism. Although the patients were believed to harbour a sporadic pituitary tumour, most of them had had signs and/or symptoms referable to one or both of the other organs involved in MEN 1, often concomitantly with those of pituitary tumours. These data indicate that the diagnosis of MEN 1 syndrome is missed in a substantial proportion of patients with prolactinomas and therefore the screening of these patients for the syndrome is strongly recommended.
S Corbetta; A Pizzocaro; M Peracchi; P Beck-Peccoz; G Faglia; A Spada
Related Documents :
21120678 - Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors f...
1796748 - Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comp...
7984218 - Systematic evaluation of the adrenocortical function in patients with paracoccidioidomy...
6299918 - Influence of neuroactive drugs on corticosteroid feedback regulation of acth secretion ...
9470078 - Right ventricular function during weaning from mechanical ventilation after coronary ar...
9073758 - Transfimbrial salpingoscopy (ssc) and laparoscopy (lsc): correlation of findings in pat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  47     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  1997 Nov 
Date Detail:
Created Date:  1998-01-26     Completed Date:  1998-01-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  507-12     Citation Subset:  IM    
Instituto di Scienze Endocrine, University of Milan, Ospedale Maggiore IRCCS, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenoma / blood,  complications
Biological Markers / blood
Calcium / blood
Gastrinoma / blood,  complications
Gastrins / blood
Hyperparathyroidism / blood,  epidemiology*
Middle Aged
Multiple Endocrine Neoplasia Type 1 / blood,  complications*,  epidemiology
Pancreatic Polypeptide / blood
Parathyroid Hormone / blood
Phosphates / blood
Pituitary Neoplasms / blood,  complications*,  epidemiology
Prolactinoma / blood,  complications*,  epidemiology
Somatostatin / blood
Vasoactive Intestinal Peptide / blood
Reg. No./Substance:
0/Biological Markers; 0/Gastrins; 0/Parathyroid Hormone; 0/Phosphates; 37221-79-7/Vasoactive Intestinal Peptide; 51110-01-1/Somatostatin; 59763-91-6/Pancreatic Polypeptide; 7440-70-2/Calcium
Comment In:
Clin Endocrinol (Oxf). 1997 Nov;47(5):513-4   [PMID:  9425389 ]
Clin Endocrinol (Oxf). 1999 Feb;50(2):272   [PMID:  10396374 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A case report of rapidly progressive fibrodysplasia (myositis) ossificans progressiva.
Next Document:  Increased thyrotrophin levels and loss of the nocturnal thyrotrophin surge in Sheehan's syndrome.